High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Chief executive Stéphane Bancel shares what’s next for Moderna after its report of a breakthrough of its cancer vaccine. He also discusses the state of the FDA and competition from China, AI integration in the drug industry and bioterrorism readiness.
Meta Platforms, Moderna and Okta rallied to fresh 52-week highs on Wednesday amid positive company catalysts and improving investor sentiment.
Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.
Moderna and Twilio climbed to multi-year highs on Wednesday, fueled by optimism around Moderna’s broader mRNA pipeline and Twilio’s emerging opportunity from the rapid adoption of AI agents.
Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development. Chief Executive Office
Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.
There's a joke on Wall Street that analysts never saw an S&P 500 stock they didn't like. Well, that doesn't seem to be the case now.
Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.
Moderna (NasdaqGS:MRNA) co-founder Bob Langer has joined the scientific advisory board of Cellular Intelligence, a biotech focused on AI-driven drug development. The appointment aligns with Cellular Intelligence's recent acquisition of a Parkinson's cell therapy program, linking AI discovery with advanced neurology research. Langer's role connects Moderna's mRNA expertise with a growing network of AI medicine collaborations involving Cellular Intelligence and its new Parkinson's therapy...
Moderna has delivered a very large 1 year share price gain, which puts fresh attention on a basic question. Is the current valuation of the stock supported by the company’s sales profile rather than just recent momentum and headlines? The stock is up a very large amount over the past 12 months, which makes the link between Moderna’s market value and its underlying sales more important for anyone thinking about valuation risk. News around mRNA products, from the mFlusiva flu vaccine launch to...
The company is looking to prove it can achieve significant success outside the coronavirus market.
Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.
Following last month's super rally, a growing number of analysts are now calling for caution.
Moderna has surged over 500% this year while its closest messenger RNA rival sits nearly flat, and a single late-October data presentation at ESMO could either cement the rally or erase it overnight.
Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.
Key TakeawaysPresidential Symposium Slot: Moderna stock jumped 12% to $173 on September 21 after Phase 3 melanoma data for its cancer vaccine, intismeran autogene, earned a spot in ESMO’s Presidential Symposium on October 24. Vaccine Clearance: The FDA cleared updated Spikevax and mNEXSPIKE shots targeting the JN.
Advanced Micro Devices, Warner Bros. Discovery and Moderna stocks surged to annual highs amid a series of positive catalysts.
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine, intismeran autogene, alongside Merck's Keytruda in high-risk melanoma patients continued to drive momentum.
Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business. Speaking at Morgan Stanley’s Global Healthcare Conference, Lefkofsky said the diagnost
Moderna Inc. (NASDAQ:MRNA) rebounded to a new three-year high on Monday, as investors began positioning their portfolios ahead of two upcoming health conferences, one of which will be held on Wednesday, September 23. In intra-day trading, the stock jumped to a new record high of $176.86 before paring gains to hover just above the $174 […]
Moderna will showcase detailed melanoma results for Intismeran at ESMO, alongside data and trial updates exploring the personalized therapy in pancreatic and lung cancers.
Moderna’s personalized cancer vaccine, intismeran autogene, will feature at the annual meeting of the European Society for Medical Oncology.
A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual Phase 3 melanoma data remains unseen. Here is why the scheduling alone is moving markets and what it signals about what that dataset might show.
CI is pairing top AI and biotech minds on its board (plus an advisory role for OpenAI's Fidji Simo) as it tests models on a Novo Nordisk drug.
As the bulls reassert their power, leading stocks like SanDisk, Coinbase, and Moderna are setting up in constructive base structures.
Moderna (MRNA) has been back in the spotlight after its appearance at the Morgan Stanley Global Healthcare Conference, where management highlighted progress across its vaccine portfolio and ongoing Phase 3 work on personalized cancer candidate intismeran. Recent trading has been volatile for Moderna, with a 1-day share price return that declined 2.55% after the latest close at US$154.04. However, a 7-day share price return of 6.99% and a 90-day gain of 140.84% indicate upward momentum that...
BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event. Gayer, who became CEO on Jan. 1, said
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
